New TNM classification (AJCC eighth edition) of bone and soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group

Abstract The standard therapy for all localized soft tissue sarcomas is surgical resection of the tumor. For patients with soft tissue sarcomas who are at high risk for recurrence and/or metastasis, perioperative chemotherapy is a potential treatment option. Adriamycin plus ifosfamide is currently the most promising chemotherapy regimen for localized soft tissue sarcomas. Randomized controlled trials and meta-analyses of adjuvant postoperative chemotherapy for soft tissue sarcomas have suggested that adjuvant chemotherapy may provide an advantage, however small, compared with surgery alone. On the other hand, recent randomized trials have demonstrated the efficacy of neoadjuvant preoperative chemotherapy using full-dose anthracycline plus ifosfamide for high-risk soft tissue sarcomas and showed survival benefits in patients with large, deep-seated and high-grade soft tissue sarcomas of the trunk and extremities. In this review, adjuvant and neoadjuvant chemotherapies for soft tissue sarcomas and future perspectives are discussed.

Download Full-text

Factors associated with the decision of operative procedure for proximal femoral bone metastasis: Questionnaire survey to institutions participating the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group

Journal of Orthopaedic Science ◽

10.1016/j.jos.2017.05.012 ◽

2017 ◽

Vol 22 (5) ◽

pp. 938-945 ◽

Cited By ~ 10

Author(s):

Nobuhito Araki ◽

Hirokazu Chuman ◽

Tomoya Matsunobu ◽

Kazuhiro Tanaka ◽

Hirohisa Katagiri ◽

...

Keyword(s):

Bone Metastasis ◽

Soft Tissue ◽

Soft Tissue Tumor ◽

Operative Procedure ◽

Study Group ◽

Femoral Bone ◽

Oncology Group ◽

Japan Clinical Oncology Group ◽

Factors Associated ◽

Tumor Study

Download Full-text

Expression of Telomerase Activity and Telomerase RNA in Human Soft Tissue Sarcomas

Archives of Pathology & Laboratory Medicine ◽

10.5858/2000-124-0393-eotaat ◽

2000 ◽

Vol 124 (3) ◽

pp. 393-397

Author(s):

Jinyoung Yoo ◽

Robert A. Robinson

Keyword(s):

Soft Tissue ◽

Soft Tissue Tumor ◽

Tertiary Care ◽

Soft Tissue Sarcomas ◽

Telomerase Activity ◽

Transcriptional Level ◽

Telomerase Rna ◽

Fresh Tissue ◽

Tissue Samples ◽

Tissue Tumor

Abstract Objective.—To investigate whether telomerase is reactivated in soft tissue tumor and whether telomerase activity is regulated at the transcriptional level. Design.—Fresh tissue samples of 24 soft tissue sarcomas were analyzed for telomerase activity by a radioactive polymerase chain reaction–based telomeric repeat amplification protocol assay and for human telomerase RNA (hTR) by an in situ hybridization assay. Setting.—Tertiary care teaching hospital. Patients.—Twenty-four patients with soft tissue tumor were surgically treated. Twelve patients had malignant fibrous histiocytoma, 5 had liposarcoma, 6 had leiomyosarcoma, and 1 had rhabdomyosarcoma. Results.—Telomerase activity was detected in 4 sarcoma samples (17%), all of which were positive for hTR. Expression of hTR was demonstrated in 13 sarcomas (54%), 4 of which were positive for telomerase and 9 of which were negative for telomerase. One (50%) of 2 grade 1 tumors, 9 (50%) of 18 grade 2 tumors, and 3 (75%) of 4 grade 3 tumors showed hTR expression. Conclusions.—The relatively low frequency of telomerase activity in soft tissue sarcomas suggests that telomerase may not play an important role in tumorigenesis in these tumors. Telomerase ladders were demonstrated only in association with tumors expressing hTR. It is noteworthy that half of the patients with grade 1 and 2 tumors expressed hTR, suggesting that telomerase RNA may be useful as a marker for identifying tumor aggressiveness earlier than the conventional histopathologic grading scale.

Download Full-text

Chinese largest cohort data from NCT03120846: Efficacy and safety of VEGFR2 inhibitor apatinib for metastatic soft tissue sarcomas.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.e22532 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. e22532-e22532

Author(s):

Jilong Yang ◽

Zhichao Liao ◽

Xinyue Liu

Keyword(s):

Soft Tissue ◽

Skin Reaction ◽

Soft Tissue Tumor ◽

Soft Tissue Sarcomas ◽

Stage Iv ◽

Progression Free Survival ◽

Efficacy And Safety ◽

Free Survival ◽

Tissue Tumor ◽

Hand Foot Skin Reaction

e22532 Background: There is no standard treatment for stage IV soft tissue tumor (STS) after the failure of Adriamycin-based chemotherapy. This opening, single-arm, multi-center phase II study (NCT03120846) assessed the efficacy and safety of Apatinib (YN968D1), a new tyrosine kinase inhibitor that targets VEGFR-2, for patients with stage IV soft tissue tumor after the failure of chemotherapy. Methods: Between September 2015 and February 2018, we recruited 42 patients with stage IV STS who had failed chemotherapy. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were progression-free survival rate (PFR), objective response rate (ORR), and disease control rate (DCR) at week 12. Secondary endpoint was overall survival (OS). Treatment-related adverse effects (AEs) were evaluated. Results: Patients (19 men, 23 women; 14-83 years, average age: 47.67years) received 500 mg apatinib on Days 1–28 of 4-week cycles (median 5.7 cycles; range: 0–23 cycles). Median follow-up was 9 months (range: 1–28 months). We assessed 42 patients for AEs and 38 for efficacy. At 12 weeks, PFR was 70% and the ORR was 26.32% (10/38) and DCR was 86.84% (33/38). For the overall responses, the ORR was 23.68% (9/38) and DCR was 57.89% (22/38). The median PFS was 7.87 months and median OS was 17.55 months. The top AEs included hypertension ( n= 18, 42.86%), hand-foot-skin reaction ( n= 15, 35.71%), Apositia (13, 30.95%), and proteinuria ( n= 11, 26.19%). No patients had grade-4 AEs. 11 (26.19%) had grade-3 AEs. 2 patients (4.76%) quit because the AE. Notably, the 26 patients (61.90%) who suffered hypertension, hand-foot-skin reaction or proteinuria had significantly longer OS than those without these AEs (20.94 vs. 8.93 months; Log Rank (Mantel-Cox) = 12.94, P= 0.0003). Conclusions: Apatinib is effective and well tolerated in patients with advanced soft tissue sarcomas. The adverse events hypertension, hand-foot-skin reaction, or proteinuria may indicate a favorable prognosis, representing a novel finding in STS patients. Clinical trial information: NCT03120846.

Download Full-text